IL308204A - Anti-nkg2d antibodies and uses thereof - Google Patents
Anti-nkg2d antibodies and uses thereofInfo
- Publication number
- IL308204A IL308204A IL308204A IL30820423A IL308204A IL 308204 A IL308204 A IL 308204A IL 308204 A IL308204 A IL 308204A IL 30820423 A IL30820423 A IL 30820423A IL 308204 A IL308204 A IL 308204A
- Authority
- IL
- Israel
- Prior art keywords
- antibodies against
- against nkg2d
- nkg2d
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163183635P | 2021-05-04 | 2021-05-04 | |
| PCT/IL2022/050453 WO2022234571A2 (en) | 2021-05-04 | 2022-05-02 | Anti-nkg2d antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308204A true IL308204A (en) | 2024-01-01 |
Family
ID=83932629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308204A IL308204A (en) | 2021-05-04 | 2022-05-02 | Anti-nkg2d antibodies and uses thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240228626A1 (https=) |
| EP (1) | EP4333889A4 (https=) |
| JP (1) | JP2024517741A (https=) |
| KR (1) | KR20240004838A (https=) |
| CN (1) | CN117396220A (https=) |
| AU (1) | AU2022269411A1 (https=) |
| BR (1) | BR112023023090A2 (https=) |
| CA (1) | CA3217726A1 (https=) |
| IL (1) | IL308204A (https=) |
| MX (1) | MX2023013017A (https=) |
| WO (1) | WO2022234571A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116199777B (zh) * | 2021-12-01 | 2025-01-28 | 北京免疫方舟医药科技有限公司 | 抗hNKG2D抗体及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008337517B2 (en) * | 2007-12-14 | 2014-06-26 | Novo Nordisk A/S | Antibodies against human NKG2D and uses thereof |
| WO2010017103A2 (en) * | 2008-08-04 | 2010-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Fully human anti-human nkg2d monoclonal antibodies |
| TWI622402B (zh) * | 2010-02-24 | 2018-05-01 | 免疫遺傳股份有限公司 | 葉酸受體1抗體類和免疫共軛物類及彼等之用途 |
| US9765151B2 (en) * | 2013-03-11 | 2017-09-19 | Cured Inc. | Method for producing monoclonal IgA antibody |
| FI3380522T3 (fi) * | 2015-11-25 | 2024-01-16 | Visterra Inc | Vasta-ainemolekyylejä april-proteiinille ja niiden käyttöjä |
| WO2018030405A1 (ja) * | 2016-08-09 | 2018-02-15 | 国立大学法人東京医科歯科大学 | Hmgb1に対する抗体、及びそれを含有するアルツハイマー病を治療又は予防するための組成物 |
| EP3927728A2 (en) * | 2019-02-21 | 2021-12-29 | Xencor, Inc. | Untargeted and targeted il-10 fc-fusion proteins |
| CN113811546B (zh) * | 2019-05-07 | 2025-03-11 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
| AR119393A1 (es) * | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
| US20210024644A1 (en) * | 2019-07-25 | 2021-01-28 | Zomedica Pharmaceuticals Corp. | N-cadherin binding molecules and uses thereof |
| CN116096754A (zh) * | 2020-05-04 | 2023-05-09 | 免疫里森公司 | 前体三特异性抗体构建体及其使用方法 |
-
2022
- 2022-05-02 AU AU2022269411A patent/AU2022269411A1/en not_active Abandoned
- 2022-05-02 BR BR112023023090A patent/BR112023023090A2/pt unknown
- 2022-05-02 US US18/558,679 patent/US20240228626A1/en active Pending
- 2022-05-02 WO PCT/IL2022/050453 patent/WO2022234571A2/en not_active Ceased
- 2022-05-02 MX MX2023013017A patent/MX2023013017A/es unknown
- 2022-05-02 IL IL308204A patent/IL308204A/en unknown
- 2022-05-02 KR KR1020237041484A patent/KR20240004838A/ko active Pending
- 2022-05-02 CA CA3217726A patent/CA3217726A1/en active Pending
- 2022-05-02 EP EP22798772.4A patent/EP4333889A4/en active Pending
- 2022-05-02 CN CN202280032427.2A patent/CN117396220A/zh active Pending
- 2022-05-02 JP JP2023566501A patent/JP2024517741A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240228626A1 (en) | 2024-07-11 |
| BR112023023090A2 (pt) | 2024-01-30 |
| EP4333889A2 (en) | 2024-03-13 |
| JP2024517741A (ja) | 2024-04-23 |
| EP4333889A4 (en) | 2025-11-12 |
| WO2022234571A3 (en) | 2022-12-29 |
| AU2022269411A1 (en) | 2023-12-21 |
| CN117396220A (zh) | 2024-01-12 |
| KR20240004838A (ko) | 2024-01-11 |
| WO2022234571A2 (en) | 2022-11-10 |
| CA3217726A1 (en) | 2022-11-10 |
| MX2023013017A (es) | 2024-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289354A (en) | Anti-cd154 antibodies and uses thereof | |
| EP4085076C0 (en) | BCMA-BINDING ANTIBODIES AND THEIR USES | |
| PT3802608T (pt) | Anticorpos anti-cd3 e utilizações destes | |
| IL283379A (en) | Anti-claudin 18.2 and anti-4-1bb bispecific antibodies and uses thereof | |
| EP3740224A4 (en) | ANTI-LILRB ANTIBODIES AND THEIR USES | |
| EP3889179A4 (en) | Bispecific antibody and use thereof | |
| EP3753953A4 (en) | CD47 SINGLE-DOMAIN ANTIBODIES AND ITS USE | |
| EP4071172A4 (en) | ANTI-LILRB1 ANTIBODIES AND ITS USES | |
| IL285626A (en) | Claudin 6 antibodies and uses thereof | |
| EP3904382A4 (en) | ANTI-IL-23P19 ANTIBODIES AND ITS USES | |
| EP4025609A4 (en) | ANTI-STEAP1 ANTIBODIES AND THEIR USES | |
| IL281297A (en) | Anti-npr1 antibodies and uses thereof | |
| EP4359442A4 (en) | ANTI-CCR8 ANTIBODIES AND THEIR USES | |
| EP4499707A4 (en) | CCR8 ANTIBODIES AND THEIR USES | |
| IL283875A (en) | Anti-il-27 antibodies and uses thereof | |
| EP4142793A4 (en) | ABCB5-SPECIFIC ANTIBODIES AND THEIR USES | |
| EP4126938A4 (en) | ANTIBODIES BINDING TO SIGLEC15 AND THEIR USES | |
| EP4244255A4 (en) | ANTI-TIGIT ANTIBODIES AND THEIR USES | |
| EP4132569A4 (en) | ANTI-PHF-TAU ANTIBODIES AND USES | |
| IL291546A (en) | Anti-kir3dl3 antibodies and uses thereof | |
| IL291280A (en) | Anti-cd371 antibodies and uses thereof | |
| IL291550A (en) | Anti-il-27 antibodies and uses thereof | |
| EP4247419A4 (en) | ANTI-MARCO ANTIBODIES AND RELATED USES | |
| EP4380631A4 (en) | Cd3 targeting antibodies and uses thereof | |
| IL288923A (en) | Anti-cd47 antibodies and uses thereof |